In addition to adjuvant chemotherapy, targeted therapies, such as inhibitors targeting human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor receptor (VEGFR), are also gradually being employed in the treatment of GC.3, 4. This evidence concerns the gene ERBB2 and gastric cancer.